Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials (Q28067583)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials	scientific article

Statements

scholarly article

1 reference

3 references

3 May 2021

25 July 2022

17 October 2022

systematic review

1 reference

1 reference

Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials (English)

1 reference

programmed cell death 1

1 reference

31 July 2019

monoclonal antibody

1 reference

27 September 2019

humanized antibody

1 reference

27 November 2019

immunological antineoplastic agent

1 reference

3 May 2021

1 reference

8 February 2021

1 reference

based on heuristic

inferred from title

Massimo Cristofanilli

7

object named as

Massimo Cristofanilli

1 reference

author name string

Ricardo Costa

1

1 reference

Benedito A. Carneiro

2

1 reference

Mark Agulnik

3

1 reference

Alfred W. Rademaker

4

1 reference

Sachin G. Pai

5

1 reference

Victoria M. Villaflor

6

1 reference

Jeffrey A. Sosman

8

1 reference

Francis J. Giles

9

1 reference

language of work or name

1 reference

publication date

11 November 2016

1 reference

31 January 2017

13 references

3 April 2019

18 June 2019

19 June 2019

31 July 2019

27 September 2019

27 November 2019

13 December 2019

15 December 2019

5 November 2020

8 February 2021

3 May 2021

25 July 2022

17 October 2022

13 references

3 April 2019

18 June 2019

19 June 2019

31 July 2019

27 September 2019

27 November 2019

13 December 2019

15 December 2019

5 November 2020

8 February 2021

3 May 2021

25 July 2022

17 October 2022

copyright license

Creative Commons Attribution 3.0 Unported

13 references

Europe PubMed Central

3 April 2019

Europe PubMed Central

18 June 2019

Europe PubMed Central

19 June 2019

Europe PubMed Central

31 July 2019

Europe PubMed Central

27 September 2019

Europe PubMed Central

27 November 2019

Europe PubMed Central

13 December 2019

Europe PubMed Central

15 December 2019

Europe PubMed Central

5 November 2020

Europe PubMed Central

8 February 2021

Europe PubMed Central

3 May 2021

Europe PubMed Central

25 July 2022

Europe PubMed Central

17 October 2022

copyright status

0 references

on focus list of Wikimedia project

0 references

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352453

25 May 2017

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352453

25 May 2017

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352453

25 May 2017

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352453

25 May 2017

Toxicities of Immunotherapy for the Practitioner

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352453

25 May 2017

Pembrolizumab for the treatment of non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352453

25 May 2017

Pembrolizumab versus Ipilimumab in Advanced Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352453

25 May 2017

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352453

25 May 2017

Nivolumab in previously untreated melanoma without BRAF mutation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352453

25 May 2017

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352453

25 May 2017

Clinical biomarkers of response in advanced renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352453

25 May 2017

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352453

25 May 2017

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352453

25 May 2017

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352453

25 May 2017

Operating characteristics of a rank correlation test for publication bias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352453

25 May 2017

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352453

29 September 2017

Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352453

29 September 2017

Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy: A Report From the US Food and Drug Administration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352453

29 September 2017

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352453

29 September 2017

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352453

29 September 2017

Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352453

29 September 2017

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352453

29 September 2017

Managing immune checkpoint-blocking antibody side effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352453

29 September 2017

Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352453

29 September 2017

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352453

29 September 2017

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352453

29 September 2017

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352453

29 September 2017

Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352453

29 September 2017

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352453

29 September 2017

Evidence for an autoimmune pathogenesis of vitiligo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352453

29 September 2017

Nivolumab-induced organizing pneumonia in a melanoma patient

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352453

2 June 2018

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352453

2 June 2018

Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352453

27 November 2018

Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352453

27 November 2018

Prognostic significance of autoimmunity during treatment of melanoma with interferon.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352453

27 November 2018

Organizing Pneumonia Induced by Nivolumab in a Patient with Metastatic Melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/27852042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of weekly paclitaxel in patients with non-small cell lung cancer who have failed previous treatments

1 reference

https://pubmed.ncbi.nlm.nih.gov/27852042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.18632/ONCOTARGET.13315

0 references

0 references

1 reference

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28067583&oldid=1974621902"